| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Adial Pharmaceuticals, Inc$3.34
+0.05 (+1.52%)
D 21Pipeline Score Pharma · Clinical
Market Cap
5.06 M
EPS
-9.90
P/E Ratio
-0.24 $
Value Trade
49.40 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
432.53 K
Operating CF
-1.61 M
Total Assets
5.23 M
Total Liabilities
1.51 M
Equity
3.72 M
D/E Ratio
12,345
52.94 %
Week
25.3 %
1 Month
-19.69 %
3 Month
-71.31 %
6 Month
-99.87 %
5 Year
-99.92 %
All Time
Cash Data
Cash Position
4.58 M
Monthly Burn
537.00 K
Runway
5.8 mo
Burn Trend
StableSEC Filing
May 8, 2026
Overview
Volume
51.60 K
52 Week Range
1.31 - 18.90
% held by Insiders
14.69 %
% held by Institutions
19.74 %
Enterprise Value
474.85 K
Total Shares
2.14 M
Short %
11.53 %
Float Shares
2.11 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Adial Pharmaceuticals, Inc
322Total events
5Upcoming
59Tier-1 (high impact)
2017 – 2027Coverage
Upcoming catalysts 2
TBD
T2Runway Guidance Update
Subscribe to view catalyst details
TBD
T2Trial Initiation
Subscribe to view catalyst details
Event history 2
TBD
◆Management ChangeCorporate
Subscribe to view catalyst details
TBD
▼Equity OfferingCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2026-02-25 | AD04 (serotonin-3 receptor antagonist) | phase 3 data readout | Phase 3 | — | – | – | – |
2026-02-25 | AD04 (serotonin-3 receptor antagonist) | phase 3 data readout | Phase 3 | — | – | – | – |
2026-02-25 | AD04 (serotonin-3 receptor antagonist) | phase 3 data readout | Phase 3 | — | – | – | – |
Drug Pipeline Intelligence
D21
Pipeline Score $0M
Pipeline ValueValuation Signal
1
Drugs Scored—
rNPV / MCap Top 21%
Micro Cap (rank 722 of 913)
Percentile RankAdial Pharmaceuticals, Inc faces pipeline headwinds (21/100), with 1 assets in development.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AD04 Small molecule | Alcohol Use Disorder | Phase 3 | NCT04101227 | 49% | - | COMPLETED | 302 | - | - | Mar 18, 2022 | - | Apr 17, 2024 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
AD04 | Alcohol Use Disorder | Phase 3 | 2026-02-17 | promising results in reducing drinking in heavy drinking patients, and no overt safety or tolerability concerns Read More | Adial Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference Read More | |
AD04 | Alcohol Use Disorder | Phase 3 | 2026-02-17 | promising results in reducing drinking in heavy drinking patients, and no overt safety or tolerability concerns Read More | Adial Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference Read More | |
AD04 | Alcohol Use Disorder | Phase 3 | 2026-02-17 | promising results in reducing drinking in heavy drinking patients, and no overt safety or tolerability concerns Read More | Adial Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ADIL
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ADIL Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ADIL▼ -10.9%on this news
Adial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE Financing
Adial Pharmaceuticals has expanded its executive leadership team by appointing Matthew Davidson as chief development officer and Julie Saiki as executive vice president of strategy. The company also announced the successful closing of a $32 million private placement, part of a larger $64 million financing effort, aimed at advancing its lead program, AT177, for ulcerative colitis.
Read more →ADIL▲ +39.9%on this newsshared move
Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing
Adial Pharmaceuticals has acquired Azora Therapeutics, enhancing its pipeline with Azora's lead asset, AT177, aimed at treating ulcerative colitis. The acquisition is coupled with a financing deal worth up to $64 million, which will support the advancement of AT177 through clinical milestones. The company plans to initiate Phase 1 studies in mid-2027, leveraging Azora's innovative approach to minimize systemic exposure.
Read more →ADILAdial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update
Adial Pharmaceuticals reported its first quarter financial results for 2026, highlighting progress in advancing its lead product, AD04, towards late-stage development. The company noted favorable regulatory discussions that could streamline the approval process and reduce costs. Additionally, a collaboration with Molteni Farmaceutici aims to establish a commercial pathway for AD04 in Europe. However, securing funding remains a critical challenge for the company's future plans.
Read more →ADILAdial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045
Adial Pharmaceuticals has filed a new U.S. utility patent application for AD04, its investigational treatment for Alcohol Use Disorder, with expectations to protect its intellectual property through at least 2045. The application includes a Request for Track One Prioritized examination, potentially expediting the patent process. CEO Cary Claiborne highlights this step as crucial for both strengthening the company's asset value and improving its position in licensing negotiations. The company aims to advance AD04 towards its next clinical phase, reflecting a comprehensive approach to its developmental strategy.
Read more →ADILAdial Pharmaceuticals Submits Application to FDA Commissioner’s National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program
Adial Pharmaceuticals has submitted an application for its AD04 product to the FDA's Commissioner’s National Priority Voucher Pilot Program, aimed at expediting the review process for drugs addressing national health priorities. The program could significantly shorten the review timeline to 1-2 months, enhancing communication with the FDA. AD04 is targeted for treating Alcohol Use Disorder and may also address other addictive disorders.
Read more →ADILAdial Pharmaceuticals Submits Application to FDA Commissioner’s National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program
Adial Pharmaceuticals has submitted an application for its AD04 product under the FDA Commissioner's National Priority Voucher Pilot Program. This program is aimed at accelerating the FDA review process for drugs targeting key U.S. health priorities. If granted, the CNPV voucher could reduce review timelines from 10-12 months to 1-2 months, enhancing communication with the FDA. The company is optimistic that this will facilitate quicker approval and market access for AD04, aimed at treating Alcohol Use Disorder among other addictions.
Read more →ADILAdial Pharmaceuticals Successfully Completes Manufacturing of Demonstration Batch Production, Enabling Clinical and Registration Production for AD04 Planned Phase 3 Trial
Adial Pharmaceuticals has successfully completed the demonstration batch production for its investigational drug AD04, which is aimed at treating Alcohol Use Disorder. This milestone allows for the upcoming Phase 3 clinical trial and facilitates necessary regulatory updates with the FDA. The successful technical transfer of manufacturing processes indicates potential efficiencies and compliance with clinical specifications. The company is focused on advancing its development efforts following this achievement and exploring AD04's potential for treating additional addictive disorders.
Read more →ADIL▼ -8.2%on this news
Adial Pharmaceuticals Commends Congress on Introduction of Bipartisan Legislation Expanding Access to Emerging AUD Therapies for Veterans
Adial Pharmaceuticals has praised the introduction of bipartisan legislation, H.R. 7091, aimed at enhancing research and development of therapies for Alcohol Use Disorder (AUD) among veterans. This legislation acknowledges the high prevalence of AUD in the veteran population and supports non-abstinence based treatment options. Adial's AD04, a genetically targeted therapy, aligns with the updated federal definition of recovery, promoting harm reduction strategies.
Read more →ADIL▼ -7.1%on this news
Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update
Adial Pharmaceuticals reported its financial results for the 2025 fiscal year, highlighting significant progress in regulatory alignment and partnerships. The company received a positive response from the FDA regarding its AD04 product, advancing it towards Phase 3 development. Additionally, Adial secured U.S.-based manufacturing partnerships and expanded its intellectual property portfolio. They also managed to reduce net loss significantly compared to the previous year, which bodes well for financial stability as they pursue new clinical trials and collaborations.
Read more →ADIL▼ -7.3%on this news· ran to -26% by day 3shared move
Adial Pharmaceuticals Signs an Exclusive AD04 Collaboration Framework with Molteni Farmaceutici for Europe which Anticipates Nearly $60 Million in Potential Royalties and Milestones upon execution of a Definitive Agreement
Adial Pharmaceuticals has signed a collaboration framework with Molteni Farmaceutici to commercialize AD04 in Europe. The agreement outlines strategic and financial terms, with potential royalties and milestones estimated at nearly $60 million. This partnership marks a significant milestone for Adial as it aims to establish a European market presence for its treatment of Alcohol Use Disorder.
Read more →ADILAdial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement
Adial Pharmaceuticals announced it has regained compliance with Nasdaq's minimum bid price requirement, following a period where its stock price exceeded $1.00 per share. This milestone supports the company's advancement of its lead drug, AD04, towards a pivotal Phase 3 clinical trial for Alcohol Use Disorder. The company is also engaged in strategic partnerships to enhance AD04's development and commercialization.
Read more →ADILAdial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One
Adial Pharmaceuticals has highlighted a recent FDA policy shift that may allow approval of its lead drug candidate, AD04, based on one pivotal trial instead of two. This change could significantly reduce the costs and time associated with Phase 3 trials, enhancing the company's strategic position. The FDA's new direction emphasizes trial quality over quantity, potentially benefiting Adial's development strategy.
Read more →ADIL▼ -5.3%on this news
Adial Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Adial Pharmaceuticals will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026. CEO Cary Claiborne will discuss the company's progress, particularly regarding its investigational drug AD04 for Alcohol Use Disorder. The presentation will be available via webcast, and management will hold one-on-one meetings with investors during the event.
Read more →ADIL▼ -8.9%on this news
Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price Requirement Common Stock Will Begin Trading on Split-Adjusted Basis on
Adial Pharmaceuticals has announced a 1-for-25 reverse stock split to comply with Nasdaq's minimum bid price requirement, effective February 5, 2026. This initiative aims to enhance the attractiveness of the company's stock for institutional and retail investors. The company remains focused on advancing its lead investigational treatment, AD04, for Alcohol Use Disorder, and is optimistic about its future strategic priorities. The reverse split will significantly reduce the number of outstanding shares while maintaining shareholder percentages, other than fractional shares.
Read more →ADILAdial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04
Adial Pharmaceuticals has praised a new Congressional directive that encourages the FDA and NIDA to establish alternative clinical trial endpoints for substance use disorders, particularly Alcohol Use Disorder (AUD). This directive aims to include measures like reduced cravings and disorder severity, which align with modern treatment goals. Adial's investigational therapy, AD04, is positioned to benefit from this regulatory evolution, potentially enhancing its development path.
Read more →ADIL▼ -25.8%on this news· ran to -42% by day 3shared move
Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement
Adial Pharmaceuticals announced a 1-for-25 reverse stock split effective February 5, 2026, to comply with Nasdaq's minimum bid price requirement. This action aims to enhance the attractiveness of its shares to investors while maintaining the ownership percentage of current shareholders. The company's CEO expressed optimism about future growth and the potential of their lead drug, AD04.
Read more →ADILAdial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement
Adial Pharmaceuticals announced a 1-for-25 reverse stock split effective February 5, 2026, to comply with Nasdaq's minimum bid price requirement. This move aims to enhance the attractiveness of its stock to investors and maintain its listing on the exchange. The company remains optimistic about its future, particularly regarding its lead drug candidate, AD04, for treating Alcohol Use Disorder.
Read more →ADILAdial Pharmaceuticals Announces Publication of International PCT Patent Application to Protect Core Assets and Extend IP Exclusivity to at least 2045
Adial Pharmaceuticals has announced the publication of an international patent application for its lead investigational drug, AD04, aimed at treating Alcohol Use Disorder. The patent, filed in July 2024, is expected to secure protection for the company's core assets until at least 2045. The company is planning a new Phase 3 clinical trial program to further advance AD04's development.
Read more →ADILAdial Pharmaceuticals Announces a Warrant Inducement Transaction for Approximately $2.86 Million in Gross Proceeds
Adial Pharmaceuticals has announced a warrant inducement agreement that will generate approximately $2.86 million in gross proceeds through the immediate exercise of existing warrants. The funds raised will be allocated for working capital and other corporate needs. This transaction is anticipated to close around December 1, 2025, pending customary conditions.
Read more →ADILAdial Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Adial Pharmaceuticals reported its third quarter 2025 results, highlighting progress on its lead investigational drug AD04 for Alcohol Use Disorder. The company successfully completed an End of Phase 2 meeting with the FDA, receiving guidance on its Phase 3 study design. The AD04 program aims to address a significant unmet medical need and has garnered legislative support for expanded evaluation criteria. However, Adial's cash position has decreased, and research expenditures are down due to reduced clinical activity.
Read more →ADILAdial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show
Adial Pharmaceuticals CEO Cary Claiborne appeared on The Big Biz Show, enhancing the company's visibility. The show aired on various major networks and streaming platforms. Adial's lead product, AD04, has shown promising results in its Phase 3 trial for Alcohol Use Disorder, indicating potential for broader applications in addiction treatment.
Read more →ADILAdial Pharmaceuticals Partners with Genomind for Precision Medicine Testing Solution
Adial Pharmaceuticals has completed the analytical validation of a cheek swab method for testing patients, marking a significant milestone for its AD04 program aimed at treating Alcohol Use Disorder. The partnership with Genomind focuses on developing a genetic test to identify suitable patients for upcoming Phase 3 trials. The FDA has confirmed that the use of this test poses Non-Significant Risk, facilitating the path towards registration and commercial application.
Read more →ADILAdial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04
Adial Pharmaceuticals has received positive feedback from the FDA regarding its End of Phase 2 meeting for AD04, a treatment for Alcohol Use Disorder. The FDA's input will guide the design of the upcoming Phase 3 clinical trial. Adial aims to implement these recommendations to enhance the program's success and is optimistic about the potential market impact of AD04.
Read more →ADILAdial Pharmaceuticals Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price Rule
Adial Pharmaceuticals has been granted a 180-day extension by Nasdaq to regain compliance with the minimum bid price requirement. The company must maintain a closing bid price of at least $1.00 per share for ten consecutive business days by March 2, 2026. This extension allows Adial to continue trading on the Nasdaq Capital Market under the symbol ADIL.
Read more →ADILAdial Pharmaceuticals Encouraged By U.S. Senate Support for Expanded Clinical Trial Endpoints Beyond Abstinence in Alcohol and Substance Use Disorder Treatments
Adial Pharmaceuticals has received positive support from the U.S. Senate for expanding clinical trial endpoints beyond abstinence in treating Alcohol Use Disorder (AUD). This legislative support encourages the FDA to consider alternative endpoints, which aligns with Adial's strategy for its investigational drug AD04. The company believes this shift will enhance the regulatory pathway for AUD treatments and address unmet medical needs.
Read more →ADILAdial Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
Adial Pharmaceuticals reported its Q2 2025 financial results and highlighted significant progress in its clinical development. The company successfully completed its End of Phase 2 meeting with the FDA, receiving crucial feedback for its upcoming Phase 3 trial of AD04, a treatment for Alcohol Use Disorder. Additionally, Adial has established manufacturing agreements to ensure supply chain robustness and is optimistic about advancing its clinical program.
Read more →ADIL, ISSUED BY ADIAL PHARMACEUTICALS, INC. ON AUGUST 14, 2025 Èxhibit 99.1 Adial Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update Glen Allen, VA
Adial Pharmaceuticals, Inc. reported its second quarter 2025 financial results and offered a business update, highlighting significant milestones in the clinical development of its lead drug AD04 for Alcohol Use Disorder (AUD). Following a positive End of Phase 2 meeting with the FDA, the company is moving towards a Phase 3 trial with a targeted approach facilitated by machine learning. Strategic partnerships for manufacturing have been secured, enhancing supply chain reliability. The potential for AD04 to become the first genetically targeted therapy for AUD positions Adial favorably in a critical market.
Read more →ADILAdial Pharmaceuticals Completes Successful EOP2 FDA Meeting
Adial Pharmaceuticals has successfully completed its End of Phase 2 meeting with the FDA, receiving positive feedback on the Phase 3 trial design for its investigational drug AD04, aimed at treating Alcohol Use Disorder. The meeting is expected to enhance Adial's position in discussions with potential partners. The company is optimistic about the upcoming Phase 3 clinical development program.
Read more →ADIL▲ +10.1%on this news· ran to +38% by day 3
Adial Pharmaceuticals Regains Compliance with Nasdaq Stockholders’ Equity Listing Requirement
Adial Pharmaceuticals has announced that it has regained compliance with Nasdaq's stockholders' equity listing requirement, maintaining a minimum of $2.5 million in equity. CEO Cary Claiborne expressed satisfaction with this achievement, emphasizing its importance for investor confidence and the company's growth strategy. Adial is focused on developing treatments for addiction, with its lead product AD04 showing promise in clinical trials.
Read more →ADIL▲ +10.1%on this news· ran to +38% by day 3shared move
Adial Pharmaceuticals Regains Compliance with Nasdaq Stockholders’ Equity Listing Requirement
Adial Pharmaceuticals has announced that it has regained compliance with Nasdaq's stockholders' equity requirement, which mandates a minimum equity of $2.5 million. This compliance is seen as a significant step in reinforcing investor confidence and supporting the company's growth strategy. The company's lead product, AD04, has shown promising results in clinical trials for treating Alcohol Use Disorder.
Read more →ADILAdial Pharmaceuticals Files PCT Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to at least 2045
Adial Pharmaceuticals has filed a PCT patent application to protect its core assets, specifically for its lead investigational drug AD04, aimed at treating Alcohol Use Disorder. This application is expected to extend intellectual property exclusivity until at least 2045. The company is preparing for an EOP2 Meeting with the FDA scheduled for July 29, 2025.
Read more →ADIL▲ +7.3%on this news· ran to +105% by day 1
Adial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for Drug Substance and Drug Product Supply
Adial Pharmaceuticals has entered into agreements with Cambrex and Thermo Fisher Scientific for the manufacturing of its lead drug candidate, AD04, aimed at treating Alcohol Use Disorder. These partnerships will support upcoming clinical trials and the New Drug Application submission to the FDA. The collaboration is expected to streamline production and ensure compliance with regulatory requirements.
Read more →ADIL▼ -26%on this news
Adial Pharmaceuticals Announces Pricing of $3.6 Million Public Offering
Adial Pharmaceuticals announced the pricing of its public offering, aiming to raise approximately $3.6 million by selling shares and associated warrants. The company plans to use the proceeds for working capital and general corporate purposes. The offering includes amendments to existing warrants, reducing their exercise price to encourage participation. Notably, Adial's lead drug, AD04, has shown promise in treating Alcohol Use Disorder.
Read more →ADIL▼ -7.1%on this news· ran to -31% by day 1shared move
Adial Pharmaceuticals Submits Briefing Package to Guide Upcoming FDA Meeting
Adial Pharmaceuticals has submitted its briefing package for the FDA's rescheduled End of Phase 2 meeting on July 29th. This meeting is crucial for aligning on the Phase 3 clinical development plan for their lead drug candidate AD04, aimed at treating Alcohol Use Disorder. A successful EOP2M is expected to bolster strategic partnership discussions, enhancing Adial's position with potential collaborators. The company remains optimistic about achieving favorable outcomes in this critical phase of development.
Read more →ADIL▼ -23.8%on this news· ran to -45% by day 3shared move
Adial Pharmaceuticals Advances Toward Phase 3 Development for AD04
Adial Pharmaceuticals has made significant progress towards initiating its Phase 3 clinical trial for AD04, aimed at treating Alcohol Use Disorder. With the collaboration of Cytel Inc., the company is implementing advanced strategies to refine their trial design, focusing on specific genetic subpopulations that could benefit from treatment. The trial, anticipated to start in late 2025, represents a strategic move to enhance the efficiency and potential regulatory success of AD04. This approach aligns with Adial's commitment to addressing the urgent need for effective addiction treatments.
Read more →ADILAdial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
Adial Pharmaceuticals, Inc. reported its financial results and business updates for the first quarter of 2025, marking significant progress towards advancing its lead drug AD04 for Alcohol Use Disorder (AUD). The company successfully completed a pharmacokinetics bridging study and received FDA confirmation for its regulatory strategy, enabling an efficient path to a Phase 3 trial. Additionally, Adial secured a development milestone payment from Adovate, bolstering its financial position. The company is preparing for an upcoming End of Phase 2 meeting with the FDA to finalize key trial aspects, which it views as a pivotal milestone.
Read more →ADILAdial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study
Adial Pharmaceuticals announced it has received a six-figure development milestone payment from Adovate, LLC, following the initiation of a Phase 1 study for the asthma treatment ADO-5030. This milestone represents the exercise of Adovate's option to acquire Purnovate, a subsidiary of Adial. Adial is also set to receive over $50 million in additional potential milestone payments, alongside royalties on net sales. The partnership aims to leverage Adial's assets while focusing on advancing its own candidate, AD04, for addiction treatment.
Read more →ADILAdial Pharmaceuticals Granted End of Phase 2 Meeting from the U.S. Food and Drug Administration
Adial Pharmaceuticals has been granted an End of Phase 2 meeting with the FDA scheduled for July 25, 2025. The purpose of the meeting is to discuss the clinical development plan for AD04, a genetic therapy aimed at treating Alcohol Use Disorder (AUD). Recent analyses have strengthened Adial's confidence in the effectiveness of AD04 for heavy drinking patients. The company aims to align with the FDA on key requirements for advancing AD04 towards Phase 3 clinical trials.
Read more →ADIL▼ -14.1%on this news
Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds
Adial Pharmaceuticals has announced a warrant inducement agreement with an institutional investor for the immediate exercise of existing Series B and C Warrants. The deal is expected to generate gross proceeds of approximately $2.75 million, which will be used for working capital and general corporate purposes. The transaction, managed by A.G.P./Alliance Global Partners, will allow the investor to receive new warrants with an exercise price set at $0.74. The closing of this transaction is projected for May 5, 2025, pending customary closing conditions.
Read more →ADIL▲ +13%on this newsshared move
Adial Pharmaceuticals Expands Intellectual Property Portfolio with New U.S. Patent Granted for Genetic-Based Treatment of Alcohol and Opioid Use Disorders
Adial Pharmaceuticals has obtained a new patent for the use of its investigational drug AD04 in treating alcohol and opioid use disorders through a genetic-based precision medicine approach. The patent, issued by the U.S. Patent and Trademark Office, covers administering AD04 to patients with specific serotonin-related gene variations to improve treatment efficacy. This development represents a significant milestone for Adial, as it aims to advance personalized treatments for addiction, addressing an urgent healthcare need. AD04 has previously demonstrated promising results in clinical trials targeting alcohol use disorder.
Read more →ADILAdial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update
Adial Pharmaceuticals reported its financial results for FY 2024, highlighting significant advancements in the development of AD04, a treatment for Alcohol Use Disorder. The company successfully completed a pharmacokinetics study and received positive FDA feedback on its registration strategy. Adial is also enhancing its intellectual property portfolio with several new patents. However, the company experienced a substantial net loss and increased research and development expenses over the past year.
Read more →ADIL▲ +20.6%on this news
Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04
Adial Pharmaceuticals announced a positive response from the FDA regarding its proposed in vitro bridging strategy for its drug candidate AD04, which is aimed at addressing addiction disorders. This feedback marks a significant regulatory milestone as it enables Adial to proceed with manufacturing clinical supplies for its upcoming Phase 3 clinical program scheduled for 2025. With the FDA's agreement on the bridging strategy, Adial aims to advance the drug towards regulatory approval and the potential market as a treatment option for patients struggling with addiction.
Read more →ADILAdial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies
Adial Pharmaceuticals has received a new U.S. patent expanding its genetic-based approach for treating and diagnosing alcohol use disorder and other drug dependencies. The patent focuses on the identification of genetic markers, allowing healthcare providers to customize treatment plans using the investigational drug AD04. This development aligns with Adial's commitment to precision medicine, facilitating targeted therapies based on patients' unique genetic profiles. CEO Cary Claiborne emphasized the potential of this approach to significantly enhance treatment efficacy for addiction-related disorders.
Read more →ADILAdial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders
Adial Pharmaceuticals has secured a new U.S. patent for its treatment approach tailored to patients with genetic markers related to opioid-related disorders. The patent, numbered 12,221,654, allows for the use of AD04, the company's investigational drug, specifically targeting individuals with the TT genotype in the serotonin transporter gene. This advancement is seen as a significant step towards developing precision medicine for addiction treatment, particularly for opioid and alcohol use disorders. CEO Cary Claiborne highlighted the potential effectiveness of AD04 in improving patient outcomes.
Read more →ADILAdial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
Adial Pharmaceuticals announced the successful completion of its AD04-103 pharmacokinetics study, which evaluated the drug AD04 for treating Alcohol Use Disorder. The results demonstrated predictable bioavailability and effective dosing without food effects. This completion is a critical step towards an End-of-Phase 2 meeting with the FDA and supports the company’s plans to pursue approval under the 505(b)(2) regulatory pathway. Additionally, Adial has developed a companion diagnostic test to identify patients who may benefit from AD04 based on specific genomic biomarkers.
Read more →ADILDecember 2021 CONFIDENTIAL Medicines f or A ddi c tion Investor Presentation January 2025 This presentation includes statements that are, or may be deemed, forward - looking statements . '' In some cases, these forward -
Adial Pharmaceuticals is preparing for significant advancements in addressing Alcohol Use Disorder (AUD) with its drug candidate AD04, a near micro-dose formulation of Ondansetron. The presentation highlights the vast unmet need for effective treatments, as over 30 million individuals in the U.S. suffer from AUD, yet current therapies fail to meet patient expectations. With high rates of treatment dissatisfaction and poor long-term outcomes associated with existing solutions, Adial aims to offer a novel approach that could improve patients' quality of life while managing their drinking behaviors.
Read more →ADILAdial Pharmaceuticals Granted Key U.S. Patent for the Treatment of Alcohol and Drug Dependence Based on Expanded Genotype Combinations
Adial Pharmaceuticals has been granted a significant U.S. patent for the treatment of alcohol use disorder (AUD) based on expanded genotype combinations related to its lead drug, AD04. This patent protects various genotype combinations identified through the company’s proprietary genetic diagnostic, which is integral to its precision medicine strategy. The granted patent not only strengthens Adial's intellectual property portfolio but also paves the way for advancing AD04 toward commercialization. Clinical trials of AD04 have demonstrated potential in reducing heavy drinking in patients with specific genotypes, highlighting the drug's relevance in addiction treatment.
Read more →ADIL▲ +15%on this news
Adial Pharmaceuticals Announces Positive Topline Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
Adial Pharmaceuticals announced positive topline results from its AD04 pharmacokinetics study, which is critical for the upcoming Phase 3 clinical trials for Alcohol Use Disorder (AUD). The study confirmed favorable bioavailability and dose-proportional increases in pharmacokinetic exposure without a food effect. These results will inform the trial design for Phase 3 studies and were achieved with a focus on optimizing the dosing regimen. The company plans to engage with the FDA to further discuss these results as part of their regulatory strategy.
Read more →ADILAdial Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
Adial Pharmaceuticals reported its financial results for Q3 2024, highlighting key advancements in its lead investigational therapy, AD04, for Alcohol Use Disorder. The company achieved a significant milestone by locking the database for a pharmacokinetics study, essential for validating AD04's dosing and safety. Furthermore, Adial announced a strategic collaboration with Boudicca Dx for a companion diagnostic test and received patent approval for its genetic diagnostic tool. However, the company also reported a larger net loss compared to the previous year, attributed primarily to rising research and development costs.
Read more →ADILAdial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer
Adial Pharmaceuticals has appointed Vinay Shah as its new Chief Financial Officer, effective November 16, 2024. Shah brings over 25 years of experience in the pharmaceutical and biopharmaceutical sectors, having previously served as CFO at Virpax Pharmaceuticals. His appointment follows the resignation of Joe Truluck, who will assist with the transition. Shah's expertise is expected to play a key role in advancing Adial's strategic goals, particularly around its lead investigational drug, AD04, for treating addiction disorders.
Read more →ADIL▼ -8.5%on this news
Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference
Adial Pharmaceuticals, a clinical-stage biopharmaceutical company, has announced its participation in the 2024 ThinkEquity Conference, scheduled for October 30. The conference will showcase various innovations and financial strategies and will feature a presentation by CEO Cary Claiborne, along with one-on-one meetings for interested investors. Adial's lead product, AD04, is being investigated for the treatment of Alcohol Use Disorder and has shown promising results in clinical trials, suggesting potential for treating other addictive disorders as well.
Read more →ADIL▼ -5.8%on this news
Adial Pharmaceuticals Receives Notice of Allowance for U.S. Patent Covering Expanded Genotype Combinations Identified Using the Company’s Genetic Diagnostic for Addiction Treatment
Adial Pharmaceuticals announced a Notice of Allowance for a new patent that expands its intellectual property for AD04, a drug targeting alcohol use disorder. This patent covers additional genotype combinations identified through a proprietary genetic diagnostic tool, enhancing the precision medicine approach. The CEO emphasized the importance of this milestone in advancing their commitment to innovative addiction treatments.
Read more →ADIL▼ -5.8%on this newsshared move
Adial Pharmaceuticals Receives Notice of Allowance for U.S. Patent Covering Expanded Genotype Combinations Identified Using the Company’s Genetic Diagnostic for Addiction Treatment
Adial Pharmaceuticals has received a Notice of Allowance for a new U.S. patent that expands its intellectual property protections for the investigational drug AD04, aimed at treating alcohol use disorder (AUD). This patent will encompass additional genotype combinations identified through the company's genetic diagnostic tool. This advancement is viewed as a significant milestone in Adial's ongoing efforts to develop targeted treatments for addiction. The drug AD04 is currently undergoing clinical evaluation and shows promise in addressing heavy drinking in patients identified with certain genetic profiles.
Read more →ADILAdial Pharmaceuticals Commends the National Institute on Alcohol Abuse and Alcoholism’s New Definition of Recovery
Adial Pharmaceuticals has praised the NIAAA for its updated definition of recovery, which emphasizes a non-abstinence approach. This aligns with Adial's lead product, AD04, aimed at treating alcohol use disorder. The new definition supports flexible treatment options, enhancing Adial's market potential. The company's recent Phase 3 trial showed promising results for AD04.
Read more →ADILAdial Pharmaceuticals Commends the National Institute on Alcohol Abuse and Alcoholism's New Definition of Recovery
Adial Pharmaceuticals has praised the National Institute on Alcohol Abuse and Alcoholism (NIAAA) for its new definition of recovery, which emphasizes non-abstinence approaches. This aligns with Adial's investigational product AD04, designed for alcohol use disorder, offering patients the option of reducing drinking instead of solely focusing on abstinence. The updated definition is seen as a validation of Adial's approach and enhances its market potential. CEO Cary Claiborne expressed optimism about increased support for programs like AD04 due to this alignment.
Read more →ADILAdial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
Adial Pharmaceuticals announced the completion of the database lock for its pharmacokinetics study of AD04, a treatment for Alcohol Use Disorder. Independent statisticians will analyze the data, with topline results expected by Q4 2024. CEO Cary Claiborne emphasized that the insights gained will influence the company's clinical strategy moving forward, including plans for further engagement with the FDA. The study involved 30 participants and compared AD04's pharmacokinetic profile against a standard product.
Read more →ADILAdial Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Adial Pharmaceuticals, a clinical-stage biopharmaceutical company, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024. CEO Cary Claiborne will present on the company's progress, including updates on its lead product, AD04, which is currently in pivotal clinical trials for the treatment of Alcohol Use Disorder. The presentation will be accessible to registered attendees and will also involve one-on-one meetings with investors throughout the event.
Read more →ADILAdial Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
Adial Pharmaceuticals provided a business update along with its Q2 2024 financial results, highlighting advancements in its AD04 drug for Alcohol Use Disorder (AUD). The company initiated a pharmacokinetics study for AD04, with results expected in Q4 2024, which will guide its Phase 3 trial. Additionally, Adial entered a collaboration with Boudicca Dx to develop a companion diagnostic test, enhancing FDA compliance. The financial results indicate a net loss, driven primarily by increased expenses in clinical trials.
Read more →ADILAdial Pharmaceuticals Signs Agreement with Boudicca Dx to Advance Regulatory Strategy for Companion Diagnostic Genetic Test for AD04
Adial Pharmaceuticals has announced a partnership with Boudicca Dx to enhance the regulatory strategy for its companion diagnostic genetic test related to AD04, aimed at treating Alcohol Use Disorder. This collaboration will ensure that the diagnostic is validated according to FDA guidelines, which is essential for the upcoming Phase 3 clinical program for AD04. The partnership is viewed as a critical step towards achieving clinical success and addressing the significant unmet need in addiction treatment. Adial’s mission is to leverage precision medicine for this purpose.
Read more →ADILAdial Pharmaceuticals Announces Last Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
Adial Pharmaceuticals announced the conclusion of patient dosing for the pharmacokinetics study of its investigational drug AD04, aimed at treating Alcohol Use Disorder. Topline results from the study are anticipated in the fourth quarter of 2024, which will inform future development and regulatory discussions. The CEO expressed optimism regarding the significance of the results for advancing AD04’s Phase 3 clinical trial.
Read more →ADILAdial Pharmaceuticals Files New Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to 2044
Adial Pharmaceuticals has filed a new patent application for its lead therapeutic agent, AD04, aimed at treating Alcohol Use Disorder. This patent application is expected to extend the protection of Adial's core assets through at least 2044, enhancing the company's intellectual property strategy. The filing comes as the company progresses in its pharmacokinetics study of AD04, which has already demonstrated promising results in a pivotal Phase 3 clinical trial. This move not only strengthens Adial's market position but also highlights its commitment to developing innovative treatments for addiction-related disorders.
Read more →ADIL▲ +23.6%on this news
Adial Pharmaceuticals Advances to Second Cohort in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
Adial Pharmaceuticals has announced its advancement to the second cohort in the pharmacokinetics study of AD04, aimed at treating Alcohol Use Disorder. This follows the successful completion of the first cohort, with topline results from the study expected in Q4 2024. The company's CEO expressed optimism regarding the progress and the study's potential insights for the upcoming Phase 3 trial. The study involves 30 volunteers and will assess the pharmacokinetic properties of AD04 compared to a reference product.
Read more →ADIL▼ -13.4%on this news
Adial Pharmaceuticals Announces Publication in Leading Peer-Reviewed Journal Supporting the Potential Efficacy of AD04 as a Precision Medicine for the Treatment of Alcohol Use Disorder
Adial Pharmaceuticals announced the publication of results from its Phase 3 ONWARD study detailing the efficacy of AD04 as a precision medicine for Alcohol Use Disorder (AUD). The findings, published in the European Journal of Internal Medicine, indicate that AD04 significantly reduced heavy drinking days in a genetically defined patient population. The study highlights AD04's safety profile, with adverse events comparable to those of the placebo, and discusses the potential for combined treatment strategies to expand the demand for AUD interventions. This positions AD04 as a promising option in the landscape of addiction therapy.
Read more →ADILAdial Pharmaceuticals Achieves Important Milestone of First Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
Adial Pharmaceuticals has announced the dosing of its first patient in a pharmacokinetics study for AD04, aimed at treating Alcohol Use Disorder. This study will help optimize design elements for the upcoming Phase 3 trials and is set to be completed by early Q4 2024. The results are anticipated to enhance the likelihood of achieving FDA approval by refining the Phase 3 trial protocol. Additionally, the company plans to engage with the FDA to discuss findings and obtain guidance moving forward.
Read more →ADILAdial CEO to Present at the Spring MicroCap Rodeo Conference on June 6th
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) has announced its participation in the Spring MicroCap Rodeo Conference on June 6, 2024, in New York City. CEO Cary Claiborne will present at the conference, which focuses on presenting investment opportunities and trends. The event will feature management meetings with approved investors and is expected to showcase approximately 25 MicroCap companies across various industries. Adial's lead product, AD04, targets addiction disorders and has shown promising Phase 3 trial results.
Read more →ADILAdial Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
Adial Pharmaceuticals reported its financial results for the first quarter of 2024, highlighting progress in its clinical development of AD04 aimed at treating alcohol use disorder (AUD). The company has initiated new Phase 3 trials for AD04 following positive FDA feedback and has secured key patents to protect its innovative treatments. Despite a notable increase in net loss due to a non-cash charge, the firm has significantly boosted its cash position, allowing for continued development efforts. Overall, the company appears focused on advancing its strategies while planning for broader applications of AD04 in addiction treatment.
Read more →ADILAdial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark Office
Adial Pharmaceuticals has been granted a significant patent by the United States Patent and Trademark Office for its proprietary genetic diagnostic method combined with its investigational drug AD04. This patent allows Adial to uniquely target the treatment of alcohol use disorder (AUD) and other drug dependencies based on specific genetic profiles. The CEO emphasized the potential market opportunity of approximately $40 billion in the U.S. for these treatments, which have shown clinically meaningful results. The company remains focused on developing personalized therapies to aid a large population impacted by addiction-related disorders.
Read more →ADIL▲ +106.2%on this news· ran to +164% by day 1
Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder
Adial Pharmaceuticals has announced the publication of a peer-reviewed article that emphasizes the promising safety and efficacy data of its lead drug AD04 for treating Alcohol Use Disorder (AUD). The study revealed a favorable liver safety profile, with no significant adverse effects or changes in biochemical markers. Additionally, high patient compliance and minimal dropout rates were reported. The publication marks a significant step towards providing targeted treatment options for patients with AUD and related liver complications.
Read more →ADILAdial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business Update
Adial Pharmaceuticals reported its financial results for 2023, highlighting significant progress in the development of its lead product, AD04, for treating Alcohol Use Disorder. The company received positive feedback from regulatory agencies in the US and EU, facilitating refinements to its clinical development plans. Adial is planning two Phase 3 trials for AD04 and is engaged in discussions for strategic partnerships to accelerate development and commercialization. Additionally, the company reported improved financial positioning following warrant exercises and decreased expenses year-over-year.
Read more →ADIL▼ -15.6%on this news· ran to -35% by day 3
Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds
Adial Pharmaceuticals announced the immediate exercise of certain warrants, generating gross proceeds of approximately $3.5 million. The warrants allow for the purchase of up to 1,150,000 shares at an exercise price of $2.82 each. Proceeds from this offering will be utilized for general corporate purposes, including regulatory activities for their lead investigational drug AD04. This strategic move indicates Adial's effort to enhance its financial position as it advances its initiatives in treating addiction disorders.
Read more →ADIL▲ +85.5%on this news· ran to +215% by day 3shared move
Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark Office
Adial Pharmaceuticals has received a new patent for its investigational drug AD04, which targets the serotonin transporter gene and is aimed at treating opioid use disorder. The patent, issued by the United States Patent and Trademark Office, expands the company's intellectual property and underlines the potential of AD04 beyond its original focus on alcohol use disorder. CEO Cary Claiborne highlighted the significance of this patent and expressed optimism about advancing AD04 toward commercialization. Adial continues to advance research into multiple addiction therapies and seeks to bolster its capabilities in the market.
Read more →ADILAdial Pharmaceuticals to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20
Adial Pharmaceuticals will present at the Winter Wrap-Up MicroCap Rodeo Conference from February 20 to 23, 2024. CEO Cary Claiborne is scheduled to speak on February 20 and will host one-on-one meetings with investors later in the week. The conference aims to connect investors with executive management teams from various MicroCap companies.
Read more →ADIL▲ +8.7%on this newsshared move
Adial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trademark Office
Adial Pharmaceuticals has received a Notice of Allowance for a new patent from the U.S. Patent and Trademark Office, enhancing its intellectual property related to a genetic diagnostic for targeting alcohol use disorder (AUD) treatment with the investigational drug AD04. The company has identified specific patient genotypes responsive to AD04, which has shown positive results in Phase 3 trials. This patent expands Adial's approach to personalize addiction treatment, tapping into a significant market potential of approximately $40 billion in the U.S. for targeted therapies.
Read more →ADILAdial Announces Appointment of Tony Goodman as Chief Operating Officer
Adial Pharmaceuticals has appointed Tony Goodman as Chief Operating Officer, a move intended to bolster the company's strategic growth initiatives. He will oversee the clinical development and commercialization efforts for Adial's lead product, AD04, which is being developed for alcohol use disorder. Goodman's extensive experience in the pharmaceutical industry, notably in business development, is expected to aid in advancing the clinical program and forming strategic partnerships. Adial's focus on addiction treatment positions them for potential growth as they approach further clinical stages.
Read more →ADILAdial Pharmaceuticals Receives Final Reimbursement Payment from Adovate
Adial Pharmaceuticals announced it has received the final reimbursement payment of $350,000 from Adovate, as per their asset purchase agreement. The company is eligible for up to $83 million in additional milestone payments related to its drug compounds, along with acquiring a 15% equity stake in Adovate. Its leading investigational drug, AD04, has shown promising results in treating Alcohol Use Disorder, which may extend its application to other addiction disorders. The announcement also highlights the financial benefits that can be realized from partnerships and development agreements.
Read more →ADILAdial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirement
Adial Pharmaceuticals, a clinical-stage biopharmaceutical company, announced that it has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires maintaining stockholders' equity of at least $2,500,000. This compliance signals a positive development for the company amidst ongoing regulatory scrutiny. Their lead product, AD04, demonstrates potential in treating Alcohol Use Disorder and is being investigated for further applications. Adial’s future compliance with Nasdaq regulations will continue to be monitored to prevent potential delisting.
Read more →ADIL▲ +7.5%on this news
Adial Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
Adial Pharmaceuticals provided a business update alongside its third quarter 2023 financial results, highlighting a focus on its lead product AD04 for treating alcohol use disorder. The company secured $4 million in funding to extend its cash runway through the fourth quarter of 2024 and received positive feedback from regulatory meetings, bolstering its plans for two concurrent Phase 3 trials. Furthermore, Adial was awarded the 2023 North American Precision Medicine for Addiction Disorders Technology Innovation Leadership Award, affirming its innovative approach. However, the company reported a net loss of $1.4 million, underscoring ongoing financial challenges as it seeks strategic partnerships for future development.
Read more →ADILAdial Pharmaceuticals Chief Medical Officer and Key Opinion Leaders to Discuss “New Aspects in Substance Use Treatment” at The Annual International Society of Addiction Medicine Conference
Adial Pharmaceuticals will present at the Annual International Society of Addiction Medicine Conference from November 2-4, 2023, in Marrakesh, Morocco. The Chief Medical Officer, Bankole Johnson, and key opinion leaders will discuss the effects of AD04, a genetically targeted therapeutic agent for Alcohol Use Disorder. The presentation will include an overview of the phase 3 clinical trial results, highlighting AD04's potential as a precision medicine.
Read more →ADILAdial Pharmaceuticals Chief Medical Officer and Key Opinion Leaders to Discuss “New Aspects in Substance Use Treatment” at The Annual International Society of Addiction Medicine Conference
Adial Pharmaceuticals has announced that its Chief Medical Officer and prominent Key Opinion Leaders will present at the Annual International Society of Addiction Medicine Conference from November 2-4, 2023, in Marrakesh, Morocco. The presentation will focus on AD04, a genetically targeted therapeutic agent aimed at treating Alcohol Use Disorder (AUD), highlighting promising Phase 3 clinical trial results that support its effectiveness. The event aims to showcase new research and practices in addiction medicine, addressing a critical public health issue related to alcohol use. Adial's efforts are positioned to potentially reduce the overall health burden of alcohol-related disorders.
Read more →ADILAddiction Experts Highlight the Need for Non-Abstinence-Based Therapies to Treat Alcohol Use Disorder in Adial Pharmaceuticals Key Opinion Leader Webinar
Adial Pharmaceuticals hosted a webinar featuring addiction experts discussing the urgent need for non-abstinence-based therapies for Alcohol Use Disorder (AUD). They highlighted the limitations of current treatment options and the importance of allowing patients to set realistic goals, such as reducing alcohol consumption. The experts are optimistic about evolving treatment paradigms that could better meet patient needs.
Read more →ADILAdial Pharmaceuticals Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Adial Pharmaceuticals has completed a private placement offering, raising approximately $4 million through the sale of 1,418,440 shares of common stock and corresponding warrants. The funds will be directed towards general corporate purposes, including support for regulatory and clinical activities related to its lead investigational drug AD04, which targets Alcohol Use Disorder. H.C. Wainwright & Co. acted as the placement agent for the offering, aligning with Nasdaq rules for at-the-market transactions. The success of the fundraising underscores investor confidence and the company's potential in the treatment of addiction-related disorders.
Read more →ADIL▼ -24.1%on this newsshared move
Adial Pharmaceuticals Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Adial Pharmaceuticals has announced a private placement of 1,418,440 shares of its common stock, raising approximately $4 million before fees. The offering is expected to close on October 24, 2023, and will fund general corporate purposes and support clinical activities for their lead drug candidate, AD04, aimed at treating Alcohol Use Disorder. The company is also preparing to file a registration statement with the SEC for the resale of the securities involved in this transaction.
Read more →ADILAdial Pharmaceuticals to Present at the Fall Foliage MicroCap Rodeo Conference on October 25th
Adial Pharmaceuticals will present at the Fall Foliage MicroCap Rodeo Conference from October 24-27, 2023. CEO Cary Claiborne is scheduled to speak on October 25 at 10:30 a.m. ET. The conference allows investors to meet with management teams from various MicroCap companies and explore investment opportunities.
Read more →ADILAdial Pharmaceuticals Awarded Notice of Allowance for Key Patent Combining Use of the Company’s Proprietary Genetic Diagnostic with AD04 to Treat Alcohol and Drug Dependence
Adial Pharmaceuticals has received a key patent for its proprietary genetic diagnostic tool, which aims to enhance the treatment of alcohol and opioid use disorders by combining it with their investigational drug AD04. This advancement is seen as a significant step towards personalized medicine in addiction therapy, potentially improving treatment outcomes for patients based on their genetic profiles.
Read more →ADILAdial Pharmaceuticals Awarded Notice of Allowance for Key Patent Combining Use of the Company’s Proprietary Genetic Diagnostic with AD04 to Treat Alcohol and Drug Dependence
Adial Pharmaceuticals has been awarded a key patent that combines its proprietary genetic diagnostic with its lead investigational drug, AD04, aimed at treating Alcohol Use Disorder (AUD) and Opioid Use Disorder (OUD). This patent represents a significant advancement in personalized medicine for addiction therapy, allowing for genetically tailored treatments. The company's CEO emphasized the potential of this combination to optimize treatment outcomes based on individual genetic profiles. Additionally, AD04 has demonstrated promising efficacy in clinical trials for reducing alcohol consumption in specific patient populations.
Read more →ADILAdial Pharmaceuticals Wins Frost & Sullivan’s 2023 North American Precision Medicine for Addiction Disorders Technology Innovation Leadership Award
Adial Pharmaceuticals has been awarded the 2023 Technology Innovation Leadership Award by Frost & Sullivan for its advancements in precision medicine for addiction disorders. The award highlights the effectiveness of Adial's lead drug candidate, AD04, particularly in patients identified through a genetic test. This recognition underscores the company's innovative approach to treating Alcohol Use Disorder and its potential to improve patient outcomes.
Read more →ADILAdial Pharmaceuticals Wins Frost & Sullivan's 2023 North American Precision Medicine for Addiction Disorders Technology Innovation Leadership Award
Adial Pharmaceuticals has been awarded Frost & Sullivan's 2023 Technology Innovation Leadership Award for its advancements in precision medicine for addiction disorders. The recognition emphasizes the company's innovative approach to treating Alcohol Use Disorder using its lead drug candidate, AD04, combined with a genetic test. The award reflects Adial's commitment to addressing the needs of patients suffering from addiction and underscores the effectiveness of their therapy in selected patient subgroups. This achievement positions Adial favorably within the competitive landscape of addiction treatment solutions.
Read more →ADIL▼ -9.8%on this news
Adial Pharmaceuticals to Host a Virtual Key Opinion Leader Webinar to Discuss the Unmet Need in Alcohol Use Disorder
Adial Pharmaceuticals, Inc. is hosting a Key Opinion Leader webinar on October 4, 2023, to discuss the unmet need for non-abstinence-based therapies in Alcohol Use Disorder (AUD). The event will feature a panel of industry experts, including Dr. Joseph Volpicelli and Mr. Jonathan Hunt-Glassman, who will share insights on the current treatment landscape. The company's investigational drug, AD04, recently showed promising results in a Phase 3 clinical trial, aimed at heavy drinking patients with specific genetic markers.
Read more →ADIL▼ -8.3%on this newsshared move
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations. The following discussion and analysis is intended as a review of significant factors affecting our financial condition and re
ADIL provides an overview of its financial condition and results of operations, highlighting the reverse stock split and the sale of its subsidiary, Purnovate, Inc. The company focuses on the development of AD04 for alcohol use disorder and has successfully completed the ONWARD Phase 3 clinical trial. However, it faces significant financial challenges, including substantial net losses and potential difficulties in securing additional funding to continue operations and development efforts.
Read more →ADIL▼ -7.3%on this news· ran to -18% by day 3
December 2021 CONFIDENTIAL Medicines f or A ddi c tion H.C. Wainwright Global Investment Conference
Adial Pharmaceuticals presented at the H.C. Wainwright Global Investment Conference, discussing its efforts in developing medications for Alcohol Use Disorder (AUD). The presentation highlighted the significant prevalence of AUD in both the U.S. and Europe, and the unmet medical needs within this population. Adial is positioning itself in a challenging market with limited competition, offering a potential new solution that addresses the shortcomings of current therapies. The company emphasizes the importance of improving treatment options for individuals impacted by addiction.
Read more →ADILAdial Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Adial Pharmaceuticals will present at the H.C. Wainwright 25th Annual Global Investment Conference from September 11-13, 2023. CEO Cary Claiborne will participate in one-on-one meetings with investors and the company's presentation will be available on-demand. Adial's lead product, AD04, is expected to target Alcohol Use Disorder and has shown promising Phase 3 trial results, potentially addressing multiple addictive disorders.
Read more →ADILAdial Pharmaceuticals Chief Medical Officer and Key Opinion Leaders to Discuss the Need for New Alcohol Use Disorder Treatments at the European Society for Biomedical Research on Alcoholism
Adial Pharmaceuticals, Inc. announced that its Chief Medical Officer and key opinion leaders will present at the European Society for Biomedical Research on Alcoholism from September 1-3, 2023, in Graz, Austria. The presentations will focus on the urgent need for new treatments for Alcohol Use Disorder, emphasizing precision medicine's potential in developing targeted therapies. Key topics include the treatment of alcohol dependence in various patient subgroups and new approaches to address alcohol cravings and consumption, highlighting the innovative strategies Adial is exploring in the treatment of addiction.
Read more →ADILAdial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements
Adial Pharmaceuticals announced that it has regained compliance with the Nasdaq's listing requirements, having met the minimum bid price and stockholders' equity criteria. The company's stock has maintained a closing bid price of $1.00 or greater for ten consecutive business days, ensuring continued listing stability. In addition, Adial's lead investigational drug AD04 has shown promising results in a recent clinical trial targeting Alcohol Use Disorder. Both compliance issues have been resolved, marking a positive step for the company.
Read more →ADILAdial Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
Adial Pharmaceuticals reported its Q2 2023 financial results, highlighting positive regulatory feedback for its lead drug candidate AD04 aimed at treating alcohol use disorder. The company has decided to focus on gaining FDA approval and plans to conduct two Phase 3 trials in parallel to expedite the process. Additionally, the sale of its subsidiary Purnovate has led to a significant reduction in cash burn rate and provided funding that is expected to support operations into early 2024. Overall, Adial is optimistic about its strategic direction and potential market impact.
Read more →ADIL▲ +5.2%on this news· ran to -19% by day 3
Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price Requirement and Reduce the Public Float Common Stock Will Begin Trading on Split-Adjusted Basis on
Adial Pharmaceuticals has announced a 1-for-25 reverse stock split to comply with Nasdaq's minimum bid price requirement, effective August 4, 2023. This move is designed to reduce the public float and make shares more attractive to investors, while maintaining the same ownership percentages for existing shareholders. The company is optimistic about its strategic initiatives, particularly surrounding its investigational drug AD04 for Alcohol Use Disorder, despite facing challenges typical of micro-cap biotech firms. As the stock begins trading on a split-adjusted basis on August 7, 2023, the company remains hopeful about future regulatory and partnership opportunities.
Read more →ADILAdial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement and Reduce the Public Float
Adial Pharmaceuticals announced a 1-for-25 reverse stock split effective August 4, 2023, to comply with Nasdaq's minimum bid price requirement. This move aims to reduce the public float and make the stock more appealing to investors. The company remains optimistic about its strategic initiatives, particularly regarding its lead drug candidate AD04 for Alcohol Use Disorder.
Read more →ADILAdial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement and Reduce the Public Float
Adial Pharmaceuticals has announced a 1-for-25 reverse stock split to comply with Nasdaq's minimum bid price requirement, effective August 4, 2023. The company intends for this action to attract a broader range of investors and enhance the attractiveness of its stock. Despite recent challenges in the capital markets, CEO Cary Claiborne expressed optimism about the company's strategic initiatives, particularly regarding its lead product AD04, which is undergoing pivotal clinical trials for Alcohol Use Disorder. Shareholder ownership remains unchanged aside from fractional shares as a result of the split.
Read more →ADIL▲ +90.3%on this news
Adial Provides Business Update Following Favorable Comments from US and EU Regulatory Meetings
Adial Pharmaceuticals provided a business update following favorable feedback from US and EU regulators regarding its clinical development plan for AD04, a treatment for Alcohol Use Disorder (AUD). The regulators confirmed the importance of AD04's endpoints and acknowledged positive study results, which may help facilitate future submissions for approval. Adial plans to conduct two Phase 3 trials and aims to streamline the regulatory process while ensuring robust efficacy data. The company is actively seeking commercial partners to support these trials and advance commercialization efforts.
Read more →ADIL▼ -5.5%on this news
December 2021 CONFIDENTIAL Medicines f or A ddi c tion
Adial Pharmaceuticals presented its focus on developing drugs for alcohol addiction at the Jefferies Healthcare Conference. The company highlighted the significant public health challenge posed by Alcohol Use Disorder (AUD), affecting millions in the U.S. alone, with a vast majority remaining undiagnosed and untreated. With limited competition and a growing market need, Adial aims to address these issues, especially considering the current treatments' ineffectiveness and associated stigma preventing individuals from seeking help.
Read more →ADILAdial Pharmaceuticals to Present at the 2023 Jefferies Global Healthcare Conference on June 9th
Adial Pharmaceuticals, a clinical-stage biopharmaceutical company, has announced that it will be presenting at the Jefferies 2023 Global Healthcare Conference from June 7-9, 2023. Cary Claiborne, the CEO, is scheduled to present on June 9, 2023, highlighting the company's focus on addiction and related disorders. The presentation will be available for live webcast and replay. Adial's lead investigational drug AD04 has shown promising results in a pivotal Phase 3 trial for treating Alcohol Use Disorder, with potential applications in other addictive behaviors.
Read more →ADIL▼ -5.5%on this news
Adial Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
Adial Pharmaceuticals, Inc. reported its financial results and business updates for Q1 2023, highlighting its ongoing meetings with U.S. and European regulatory agencies. The company received a cash infusion of $0.45 million as part of the sale of its Purnovate assets, aimed at focusing resources on its lead product AD04, which targets Alcohol Use Disorder. Despite reporting a decrease in cash reserves and continuing net losses, Adial maintains confidence in its regulatory strategy and partnership potential, while actively engaging The Keswick Group to support its business development efforts.
Read more →ADILAdial Pharmaceuticals Receives Notice of Exercise from Adovate for the Acquisition of Purnovate’s Assets and Business
Adial Pharmaceuticals has announced that Adovate LLC will exercise its option to acquire the assets of its subsidiary, Purnovate, effective May 16, 2023. The deal involves an upfront payment of $450,000 and potential milestone payments that could total $83 million. This transaction enables Adial to reduce its cash burn and concentrate resources on its leading compound, AD04. The formation of Adovate aims to expedite the development of Purnovate's drug candidates, which have shown promising preclinical efficacy.
Read more →ADILAdial Pharmaceuticals Reports 2022 Fiscal Year Financial Results and Provides Business Update
Adial Pharmaceuticals reported its financial results for the fiscal year 2022, highlighting advancements in their AD04 clinical trial targeting Alcohol Use Disorder. The company secured meetings with regulatory bodies in the U.S. and Europe to discuss the path toward approval. Despite a significant net loss and diminished cash reserves from the previous year, Adial aims to strengthen its financial position through a potential asset sale and strategic partnerships to advance its drug development efforts.
Read more →ADILAdial Pharmaceuticals Engages The Keswick Group to Advance Partnering Activities for the Clinical Development of AD04 for Alcohol Use Disorder
Adial Pharmaceuticals has engaged The Keswick Group to support its partnering activities for the clinical development of AD04, a treatment for Alcohol Use Disorder. This decision follows promising results from the ONWARD trial, which showed a significant reduction in heavy drinking among certain genotypes. The Keswick Group, led by board member Tony Goodman, will focus on identifying strategic partners to enhance market entry for AD04. Despite potential benefits, the company acknowledges various risks associated with regulatory approvals and the commercialization process.
Read more →ADILAdial Pharmaceuticals to Present at the 35th Annual Roth Conference on March 14th
Adial Pharmaceuticals, a clinical-stage biopharmaceutical company, announced that its CEO Cary Claiborne will present at the 35th Annual Roth Conference on March 14, 2023. The presentation will focus on the company’s efforts in developing therapies for addiction, especially its lead product AD04, which has shown promising results in clinical trials. Additionally, Mr. Claiborne will be available for investor meetings during the conference, facilitating further discussion on the company's pipeline and initiatives.
Read more →ADILAdial Pharmaceuticals Provides Update on Regulatory Strategy for AD04 for Treatment of Alcohol Use Disorder
Adial Pharmaceuticals provided an update on its regulatory strategy for AD04, targeting approvals in the U.S. and Europe for the treatment of Alcohol Use Disorder. The company announced a confirmed Type C meeting with the FDA for Q2 2023 and plans to engage with several European regulatory authorities. Encouraging outcomes from the ONWARD trial demonstrated significant efficacy in a specific subgroup of patients, prompting positive adjustments to market valuation. Adial is also actively engaging potential partners to support its clinical and commercialization efforts, aiming to bring AD04 to market efficiently.
Read more →ADILAdial Pharmaceuticals Schedules Business Update Conference Call
Adial Pharmaceuticals announced it will host a conference call on March 7, 2023, to provide an update on its regulatory and partnering strategies for the U.S. and Europe. The call will also cover insights from the subgroup analysis of its ONWARD data, which pertains to its investigational drug AD04 aimed at treating Alcohol Use Disorder. This event indicates the company's active progress in drug development and market strategy communication.
Read more →ADILAdial Pharmaceuticals Announces Closing of $0.75 Million At-The-Market Registered Direct Offering
Adial Pharmaceuticals has completed a registered direct offering, raising $0.75 million through the sale of 1,829,269 shares at a price of $0.41 per share. This offering was executed with a single institutional investor as part of a shelf registration. Furthermore, Adial's lead product, AD04, is undergoing clinical trials aimed at treating Alcohol Use Disorder and has shown encouraging results in reducing heavy drinking. Nonetheless, the company acknowledges various risks linked to the development and regulatory approval of its product candidates.
Read more →ADILAdial Pharmaceuticals Announces Pricing of $0.75 Million At-The-Market Registered Direct Offering
Adial Pharmaceuticals has entered into a securities purchase agreement for a $0.75 million at-the-market registered direct offering of its common stock. The agreement involves the sale of approximately 1.83 million shares at a price of $0.41 per share. The offering is set to close on or about February 24, 2023, pending satisfaction of customary conditions. Adial's lead product candidate, AD04, is being explored for its potential in treating Alcohol Use Disorder and other addictive conditions.
Read more →ADILAdial Pharmaceuticals Confirms Scheduling of Meetings with FDA and European Regulatory Agencies to Advance Clinical Development of AD04 for Alcohol Use Disorder
Adial Pharmaceuticals has confirmed the scheduling of Type C meetings with the FDA and various European regulatory authorities to further the clinical development of AD04 for alcohol use disorder. The meetings aim to clarify the regulatory path toward potential approval in the U.S. and Europe. With promising results from previous clinical trials, Adial is optimistic about securing the necessary guidance for advancing their drug AD04, which also has the potential to treat other addictions.
Read more →ADILAdial Pharmaceuticals Enters Into Option Agreement for Sale of Purnovate Assets to Adenomed
Adial Pharmaceuticals has entered into an option agreement for the sale of its subsidiary Purnovate's assets to a new company, Adenomed, led by former Adial CEO William Stilley. If the option is exercised, Adial would receive an initial payment of $450,000 along with additional potential milestone payments totaling up to $83 million. This financial arrangement is intended to reduce Adial's burn rate and extend its cash runway, while the company continues to advance its late-stage clinical development for the alcohol use disorder treatment, AD04.
Read more →ADILAdial Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
Advancing submission of AD04 ONWARD™ phase 3 results to regulatory agencies Actively exploring potential partnership opportunities for AD04 and Purnovate compounds Promoted Cary Claiborne to President and Chief Executive Officer CHARLOTTESVILLE, Va., Nov. 14, 2022 (GLOBE NEWSWI
Read more →ADILAdial Pharmaceuticals Announces Positive In Vivo Data for Purnovate’s PNV-5030 as a Potential Treatment for Chronic Pain
CHARLOTTESVILLE, Va., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today announced that Purnovate, Inc., a subsidiary of Adial focused on developing novel molecules targeting the adenosine receptors for the treat
Read more →ADILAn Adial Company Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovate's PNV-5030 as a Potential Treatment for Chronic Pain PNV-5030 significantly reduced pain compared to both placebo and acetaminophen Cha
Pharmaceuticals Announces Positive In Vivo Data for Purnovate's PNV-5030 as a Potential Treatment for Chronic Pain significantly reduced pain compared to both placebo and acetaminophen VA - September 26, 2022 - Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) ("Adial" or the
Read more →ADILAdial Pharmaceuticals Announces Positive In-Vivo Non-clinical Data with Purnovate’s PNV-6005 as a Potential Treatment for Ulcerative Colitis
CHARLOTTESVILLE, Va., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today announced that Purnovate, Inc., a subsidiary of Adial focused on developing novel molecules targeting the adenosine receptors for the treat
Read more →ADILAdial Pharmaceuticals Names Cary Claiborne as Chief Executive Officer
Kevin Schuyler appointed Chairman of Adial’s Board William Stilley moves to post of CEO of Adial’s subsidiary, Purnovate Company to host conference call at 8:30 a.m. EDT tomorrow CHARLOTTESVILLE, Va., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL;
Read more →ADILAdial Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results
Reported positive topline results for ONWARD™ Phase 3 trial of AD04 for the treatment of Alcohol Use Disorder Pursuing submission of ONWARD™ results with both European and U.S. regulatory agencies Actively exploring potential partnership opportunities for AD04 Ended second qua
Read more →ADILAdial Pharmaceuticals Announces Topline Results For Onward™ Phase 3 Trial for AD04 in Patients with Alcohol Use Disorder
AD04 achieved statistically significant mean reduction in heavy drinking days among pre-specified group of heavy drinkers, compared to placebo, with an approximately 79% reduction from baseline drinking AD04 demonstrated statistically significant difference in AUD severity, as c
Read more →ADILAdial Pharmaceuticals to Announce Topline Results of ONWARD™ Phase 3 Trial for AD04 in Patients With Alcohol Use Disorder
CHARLOTTESVILLE, Va., July 18, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, to
Read more →ADILAdial Pharmaceuticals Provides Letter to Shareholders From CEO William Stilley
CHARLOTTESVILLE, Va., June 28, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today issued the following letter to its shareholders from the Company’s CEO, William Stilley. It continues to be my great honor to serve you as
Read more →ADILAdial Pharmaceuticals Announces Database Lock for the ONWARD™ Phase 3 Clinical Trial
CHARLOTTESVILLE, Va., June 27, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, to
Read more →ADILAdial Pharmaceuticals Awarded Additional U.S. Patent Combining the Use of the Company’s Proprietary Genetic Diagnostic With AD04 to Treat Alcohol and Drug Dependence
CHARLOTTESVILLE, Va., June 14, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, to
Read more →ADILAdial Pharmaceuticals Announces Research Collaboration with the Medical College of Wisconsin to Advance Purnovate’s Adenosine Compounds as Potential Treatments for Diabetes and NASH
CHARLOTTESVILLE, Va., May 19, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today announced that Purnovate, Inc., an Adial company focused on developing novel molecules targeting the adenosine receptors for the treatment of
Read more →ADILAdial Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results
Nears completion of ONWARD™ Phase 3 pivotal trial of AD04 for the treatment of Alcohol Use Disorder; on track to report Phase 3 results in the current quarter Ended first quarter with cash and cash equivalents of $12.7 million CHARLOTTESVILLE, Va., May 16, 2022 (GLOBE NEWSWIRE)
Read more →ADILAdial Pharmaceuticals Announces Research Collaboration with UC San Diego to Advance Purnovate’s Adenosine Compounds as Potential Treatments for Inflammatory Diseases & Disorders
CHARLOTTESVILLE, Va., May 04, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today announced that Purnovate, Inc., an Adial company focused on developing adenosine analogs for the treatment of major unmet medical needs, has
Read more →ADILAdial Pharmaceuticals CEO to Participate in a Fireside Chat at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th
CHARLOTTESVILLE, Va., March 22, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, t
Read more →ADILAdial Pharmaceuticals Announces Completion of Last Patient, Last Visit in its ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use Disorder
CHARLOTTESVILLE, Va., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, to
Read more →ADILAdial Pharmaceuticals Announces Closing of $10 Million Financing
CHARLOTTESVILLE, Va., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, to
Read more →ADILAdial Pharmaceuticals Announces Pricing of $10 Million Registered Direct Offering
CHARLOTTESVILLE, Va., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, to
Read more →ADILAdial Pharmaceuticals Announces Positive In Vivo Data for Purnovate’s PNV-5032 as a Potential Treatment for Asthma
CHARLOTTESVILLE, Va., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Purnovate, Inc., a wholly owned subsidiary of Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today announced positive in vivo data for PNV-5032, as a potential treatment for asthma. PNV-5032 de
Read more →ADILAdial Pharmaceuticals Receives Notice of Allowance on U.S. Patent for the Treatment for Opioid Use Disorder Using AD04
CHARLOTTESVILLE, Va., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, to
Read more →ADILAdial Pharmaceuticals to Present at the H.C. Wainwright BioConnect 2022 Conference
CHARLOTTESVILLE, Va., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, to
Read more →ADILAdial Pharmaceuticals Completes Private Placement of Common Stock at $4.00 Per Share
CHARLOTTESVILLE, Va., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, to
Read more →ADILAdial Announces Cary J. Claiborne, a Renowned Pharmaceutical Executive and Current Board Member, has Joined the Company as Chief Operating Officer
CHARLOTTESVILLE, Va., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the appointme
Read more →ADILAdial Pharmaceuticals Announces Positive Pre-Clinical Data for PNV2 as a Drug Candidate for Triple Negative Breast Cancer
CHARLOTTESVILLE, Va., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, to
Read more →ADILAdial Pharmaceuticals Announces Private Placement of Common Stock at $4.00 Per Share and Cash Exercise of Stock Options
CHARLOTTESVILLE, Va., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, to
Read more →ADILAdial Pharmaceuticals Schedules Conference Call to Provide Clinical Update and Discuss Latest Developments
CHARLOTTESVILLE, Va., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, to
Read more →ADILAdial Appoints Renowned Pharmaceutical Executive Cary J. Claiborne to Board of Directors
CHARLOTTESVILLE, Va., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the appointme
Read more →ADILAdial Announces Positive Pre-Clinical Data for Purnovate’s PNV-5030 as a Drug Candidate for the Treatment of Pain
Results suggest potential of PNV-5030 as both a standalone and combination therapy to reduce or eliminate opioid use and achieve meaningful pain reduction Clinical trial expected to commence in 2022 CHARLOTTESVILLE, Va., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals,
Read more →ADILAdial Pharmaceuticals to Present at Dawson James Securities 6th Annual Small Cap Growth Conference on October 21, 2021
CHARLOTTESVILLE, Va., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, to
Read more →ADILAdial Pharmaceuticals Announces Greater Than 50% of Patients Expected to Complete ONWARD™ Phase 3 Trial of AD04 for the Treatment of Alcohol Use Disorder Have Completed the Full 24-Week Treatment Period – Trial Completion Anticipated Q1 2022
CHARLOTTESVILLE, Va., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, a
Read more →ADILAdial Pharmaceuticals Announces Research Collaboration Agreement with the University of Virginia to Advance Next Generation Adenosine Compounds for Wound Healing
CHARLOTTESVILLE, Va., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, t
Read more →ADILAdial CEO William Stilley Invited to Participate in Maxim Group’s Virtual Panel Series Conference: “Disruptors in the Mental Health Space”
CHARLOTTESVILLE, Va., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, t
Read more →ADILAdial Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
CHARLOTTESVILLE, Va., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, t
Read more →ADILAdial Pharmaceuticals Exceeds Enrollment Target in ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use Disorder
CHARLOTTESVILLE, Va., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, an
Read more →ADILAdial Pharmaceuticals Reaches Full Enrollment Target for ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients With Alcohol Use Disorder
On track for trial completion in the first quarter of 2022 Adial to host business update call at 11AM Eastern today CHARLOTTESVILLE, Va., Aug. 20, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmace
Read more →ADILAdial Pharmaceuticals to Host Conference Call Today at 11AM Eastern to Provide Clinical Update and Discuss Positive Business Developments
CHARLOTTESVILLE, Va., Aug. 20, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, wi
Read more →ADILAdial Pharmaceuticals Schedules Conference Call to Provide Clinical Update and Discuss Positive Business Developments
CHARLOTTESVILLE, Va., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, to
Read more →ADILAdial Pharmaceuticals Awarded U.S. and International Patents for the Treatment Of Alcohol and Opioid Use Disorders Using AD04
CHARLOTTESVILLE, Va., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, to
Read more →ADILAdial Pharmaceuticals Announces Closing of $5 Million Private Placement Priced at a Premium to Market
CHARLOTTESVILLE, Va., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, to
Read more →ADILAdial Pharmaceuticals Reports CEO Op-Ed Featured on Nasdaq.com
CHARLOTTESVILLE, Va., July 29, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that an op-ed from Adial’s CEO, William Stilley, has been
Read more →ADILAdial Announces Positive Pre-Clinical Data for its Adenosine Pain Platform
Data merits further testing for pain reduction as a possible alternative to opioids Validation of Purnovate acquisition CHARLOTTESVILLE, Va., July 14, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused
Read more →ADILAdial Announces $5,000,000 Above Market Private Placement at $3.00 Per Share
CHARLOTTESVILLE, Va., July 07, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that the Company has entered into Securities Purchase Agr
Read more →ADILThe Phase 3 ONWARD Trial Meets its Screening Target and Nears Enrollment Completion Study Drug Continues to Appear to be Well-Tolerated Patient Retention Currently Exceeds Expectations Charlottesville, VA
The Phase 3 ONWARD Trial Meets its Screening Target and Nears Enrollment Completion Study Drug Continues to Appear to be Well-Tolerated Patient Retention Currently Exceeds Expectations Charlottesville, VA - July 06, 2021 - Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a
Read more →ADILAdial Joins Russell Microcap Index
CHARLOTTESVILLE, Va., June 28, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, to
Read more →ADILAdial Pharmaceuticals Provides Regulatory and Development Update
CHARLOTTESVILLE, Va., June 24, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that it has received correspondence related to its reques
Read more →ADILAdial Pharmaceuticals Plans to Enter Genetic Testing Market Following Allowance of U.S. Patent for Genetic Diagnostic Test
CHARLOTTESVILLE, Va., June 22, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced plans to ente
Read more →ADILAdial Pharmaceuticals Comments on Article in ‘The Atlantic,’ Highlighting the Second Pandemic of Addiction
CHARLOTTESVILLE, Va., June 07, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, co
Read more →ADILAdial Announces Funding of Management-Led $2,100,000 Above Market Private Placement at $3.00 Per Share
CHARLOTTESVILLE, Va., June 03, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, to
Read more →ADILAdial Pharmaceuticals Featured on Multiple News Broadcasts Nationwide Regarding the Second Pandemic of Alcohol Use Disorder
CHARLOTTESVILLE, Va., May 18, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial”), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that William Stilley, Chief Executive Officer, a
Read more →ADILAdial Founder and Chief Medical Officer Dr. Bankole Johnson Featured Guest on The Black News Channel
CHARLOTTESVILLE, Va., March 17, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, t
Read more →ADILAdial Announces Management-Led $2,100,000 Above Market Private Placement at $3.00 Per Share
CHARLOTTESVILLE, Va., March 15, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, t
Read more →ADILAdial Schedules Town Hall to Discuss Positive Updates Regarding Pharmaceutical Pipeline and Business Expansion
CHARLOTTESVILLE, Va., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial”), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that it will host a Town Hall at 1 P.M., Easter
Read more →ADILAdial Receives $1.425 Million in Net Proceeds from Exercise of Warrants
CHARLOTTESVILLE, Va., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced the exercise of 712,500 warran
Read more →ADILAdial Pharmaceuticals Achieves 50% Enrollment in ONWARD™ Phase 3 Trial
CHARLOTTESVILLE, Va., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that it has reached 50% enrollment in the Company’s landm
Read more →ADILAdial to File Fast Track Application for AD04 with the FDA
CHARLOTTESVILLE, Va., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that it will be filing an appl
Read more →ADILAdial Pharmaceuticals Closes Acquisition of Purnovate Acquisition Expands Adial's Portfolio with Drug Candidates for Treatment of Pain and Addiction Charlottesville, VA
Pharmaceuticals Closes Acquisition of Purnovate Expands Adial's Portfolio with Drug Candidates Treatment of Pain and Addiction VA - January 26, 2021 - Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focu
Read more →ADILAdial Pharmaceuticals Enters Agreement to Acquire Purnovate, a Developer of Potential Therapies for Non-Opioid Pain Reduction and Treatment of Addiction Charlottesville, VA
Pharmaceuticals Enters Agreement to Acquire Purnovate, a Developer of Potential Therapies for Non-Opioid Pain Reduction and Treatment VA - December 10, 2020 - Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) ("Adial" or the "Company"), a clinical-stage biopharmaceutical compan
Read more →ADILAdial Pharmaceuticals Provides Update on its ONWARD Pivotal Phase 3 Trial of AD04 for Treatment of Alcohol Use Disorder ONWARD Projected to be Fully Enrolled During Q2 2021 Charlottesville, VA
Pharmaceuticals Provides Update on its ONWARD Pivotal Phase 3 Trial of AD04 for Treatment of Alcohol Use Disorder Projected to be Fully Enrolled During Q2 2021 VA - November 03, 2020 - Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical compa
Read more →ADILAdial Pharmaceuticals Announces FDA Reactivation of its Investigational New Drug Application for AD04 in Alcohol Use Disorder Charlottesville, VA
Adial Pharmaceuticals Announces FDA Reactivation of its Investigational New Drug Application for AD04 in Alcohol Use Disorder Charlottesville, VA - October 21, 2020 - Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the
Read more →ADILAdial Pharmaceuticals Announces COVID-19 Point-of-Care Antibody Test Granted First Ever FDA Emergency Use Authorization for Use with Fingerstick Blood Samples Charlottesville, VA
Adial Pharmaceuticals Announces COVID-19 Point-of-Care Antibody Test Granted First Ever FDA Emergency Use Authorization for Use with Fingerstick Blood Samples Charlottesville, VA - September 29, 2020 - Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biophar
Read more →ADILAdial Pharmaceuticals Files for Expedited Review of AD04 with the FDA Charlottesville, VA
Adial Pharmaceuticals Files for Expedited Review of AD04 with the FDA Charlottesville, VA - September 25, 2020 - Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announ
Read more →ADILAdial Pharmaceuticals and iRemedy Partner to Sell COVID-19 Antibody Test Kits to U.S. Medical Providers and Commence Sales Charlottesville, VA
Adial Pharmaceuticals and iRemedy Partner to Sell COVID-19 Antibody Test Kits to U.S. Medical Providers and Commence Sales Charlottesville, VA - September 22, 2020 - Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the d
Read more →ADILAdial Pharmaceuticals Announces Third-Party Sales and Distribution Agreement with Brik for Rapid Result COVID-19 Antibody Test Kits Charlottesville, VA
Adial Pharmaceuticals Announces Third-Party Sales and Distribution Agreement with Brik for Rapid Result COVID-19 Antibody Test Kits Charlottesville, VA - August 6, 2020 - Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) ("Adial"), a clinical-stage biopharmaceutical company
Read more →ADILAdial Pharmaceuticals Announces Approval to Commence Landmark ONWARD Pivotal Phase 3 Trial in Poland Achievement of Poland Approval an Important Milestone in Advancement of Trial Trial Progress Accelerates as Host Countr
Adial Pharmaceuticals Announces Approval to Commence Landmark ONWARD Pivotal Phase 3 Trial in Poland Achievement of Poland Approval an Important Milestone in Advancement of Trial Trial Progress Accelerates as Host Countries Reopen Following COVID-19 Lockdowns Charlottesvil
Read more →ADILAdial Pharmaceuticals Announces Pricing of $5.2 Million Registered Direct Offering Priced At-The-Market CHARLOTTESVILLE, VA / ACCESSWIRE /
Pharmaceuticals Announces Pricing of $5.2 Million Registered Direct Offering Priced At-The-Market VA / ACCESSWIRE / June 9, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial" or the "Company"), a biopharmaceutical company focused on the development of treatments f
Read more →ADILAdial Pharmaceuticals and BioLab Sciences Enter into Distribution Agreement for COVID-19 Antibody Tests Antibody Testing Available for Landmark ONWARD Ô Pivotal Phase 3 Trial Participants BioLab Sciences Grants Adi
Adial Pharmaceuticals and BioLab Sciences Enter into Distribution Agreement for COVID-19 Antibody Tests Antibody Testing Available for Landmark ONWARD Pivotal Phase 3 Trial Participants BioLab Sciences Grants Adial Exclusive Rights to Sell and Distribute Rapid Result COVID-
Read more →ADILAdial Pharmaceuticals Commences Phase 3 Trial of AD04 for Alcohol Use Disorder Charlottesville, VA
Adial Pharmaceuticals Commences Phase 3 Trial for Alcohol Use Disorder Charlottesville, VA - February 6, 2020 - Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announce
Read more →ADILMEDICINES FOR ADDICTION May 2019 Investor Presentation Nasdaq: ADIL
MEDICINES FOR ADDICTION May 2019 Investor Presentation Nasdaq: ADIL 2 This presentation includes statements that are, or may be deemed, forward - looking statements.'' In some cases, these forward - l ooking statements can be identified by the use of forward - looking terminolog
Read more →ADILAdial Pharmaceuticals Announces Appointment of Bankole Johnson, M.D., as Chief Medical Officer CHARLOTTESVILLE, Va.
Pharmaceuticals Announces Appointment of Bankole Johnson, M.D., as Chief Medical Officer Va., March 26, 2019 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of medicines for addiction,
Read more →ADILAdial Pharmaceuticals Featured on CBS in San Francisco
CHARLOTTESVILLE, Va., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, announced that William Stilley, President and Chief Executive Officer, appe
Read more →ADILPharmaceuticals Announces Pricing of $8.0 Million Underwritten Public Offering
Pharmaceuticals Announces Pricing of $8.0 Million Underwritten Public Offering Va., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL;ADILW), a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announc
Read more →ADILAdial Pharmaceuticals Announces Closing of $9.2 Million Underwritten Public Offering and Exercise of Underwriters’ Over-Allotment Option
Proceeds from Offering Expected to Fully Fund Initial Phase 3 Trial of AD04 CHARLOTTESVILLE, Va., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL;ADILW), a clinical-stage biopharmaceutical company focused on the development of medicines for addiction,
Read more →ADILAdial Pharmaceuticals Announces Pricing of $8.0 Million Underwritten Public Offering
CHARLOTTESVILLE, Va., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL;ADILW), a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced the pricing of an underwritten public offering of 2,475,000 s
Read more →ADILAdial Pharmaceuticals Announces Partnership with Catalent to Package and Distribute Adial’s AD04 for its Phase 3 Trial
CHARLOTTESVILLE, Va., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL;ADILW) www.adialpharma.com, a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced a partnership with Catalent Pharma Soluti
Read more →ADILAdial Pharmaceuticals Submits Continuation Patent Application for Use of AD04 in Opioid Dependence and Abuse
Continuation patent would allow for broader protection beyond claims protected under current patents CHARLOTTESVILLE, Va., Feb. 15, 2019 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL;ADILW), a clinical-stage biopharmaceutical company focused on the development of
Read more →ADILAdial Pharmaceuticals Appoints Leading Addiction Specialist to its Scientific Advisory Board to Advance AD04 and Combat Alcohol Use Disorder
Distinguished Professor Markus Heilig joins an accomplished assemblage of addiction specialists including Dr. Giovanni Addolorato and Professors Hannu Alho, Tomas Zima and Sebastian Mueller CHARLOTTESVILLE, Va., Feb. 12, 2019 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASD
Read more →ADILAdial Pharmaceuticals CEO to Appear on CBS and Fox Affiliates to Discuss AD04 as a Potential Treatment for Alcohol and Opioid Use Disorder
Scheduled to appear today on KSWB-TV FOX 5 Morning News in San Diego at 10:40 AM ET/7:40 AM PT Additional appearance scheduled on KPIX-TV (CBS-CW) “Bay Area Focus” morning show February 3rd during the 2:00 PM ET/11:00 AM PT hour CHARLOTTESVILLE, Va., Feb. 01, 2019 (GLOBE NEWSWI
Read more →ADILAdial Pharmaceuticals Receives $1.2 Million
Adial Pharmaceuticals Receives $1.2 Million in Proceeds Through the Exercise of Warrants Enhances Balance Sheet; Funds to be Utilized for Phase 3 Clinical Trial of AD04 Charlottesville, VA - January 24, 2019 - Adial Pharmaceuticals, Inc. (NASDAQ:ADIL;ADILW) www.adialpharma.c
Read more →ADILAdial Pharmaceuticals Receives $1.2 Million in Proceeds Through the Exercise of Warrants
Enhances Balance Sheet; Funds to be Utilized for Phase 3 Clinical Trial of AD04 CHARLOTTESVILLE, Va., Jan. 24, 2019 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL;ADILW) www.adialpharma.com, a clinical-stage biopharmaceutical company focused on the development of m
Read more →ADILAdial Pharmaceuticals Appoints Two Additional Global Thought Leaders to its Scientific Advisory Board to Advance AD04 and Combat Alcohol Use Disorder
CHARLOTTESVILLE, Va., Jan. 17, 2019 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced that it has appointed Professor Tomáš Zima, MD, DSc, Dr.h.c.
Read more →ADILAdial Pharmaceuticals to Present at The 2019 Wall Street Conference
CHARLOTTESVILLE, Va., Jan. 10, 2019 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), www.adialpharma.com, a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced that William Stilley, President and Chi
Read more →ADILAdial Pharmaceuticals Retires All Outstanding Debt
CHARLOTTESVILLE, Va., Dec. 24, 2018 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL;ADILW), www.adialpharma.com, a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced that the holder of the sole remaining,
Read more →ADILAdial Pharmaceuticals Announces Amendment to License Agreement with the University of Virginia Licensing & Ventures Group
CHARLOTTESVILLE, Va., Dec. 19, 2018 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), www.adialpharma.com, a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced that it has amended its license agreem
Read more →ADILAdial Pharmaceuticals Announces Planned Expansion of Lead Asset AD04 into Opioid Addiction Including Synthetic Opioids Such as Fentanyl
CHARLOTTESVILLE, Va., Dec. 13, 2018 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), www.adialpharma.com, a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced plans to expand activities around the C
Read more →ADILAdial Pharmaceuticals Announces Professor Hannu Alho, Emeritus Professor of Addiction Medicine at the University of Helsinki, Finland as Coordinating Principal Investigator for Phase 3 Clinical Trial of AD04 for the Treatment of Alcohol Use Disorder
CHARLOTTESVILLE, Va., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) www.adialpharma.com a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced that Professor Hannu E.R. Alho, Emeritus
Read more →ADILAdial Pharmaceuticals Establishes Scientific Advisory Board and Appoints Global Thought Leader in the Field of Alcohol Use Disorder
CHARLOTTESVILLE, Va., Nov. 29, 2018 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), www.adialpharma.com, a clinical-stage biopharmaceutical company focused on the development of a therapeutic agent for the treatment of alcohol use disorder, today announced t
Read more →ADILAdial Pharmaceuticals Chairman Featured in Doctors Channel Video Discussing Alcohol Use Disorder
CHARLOTTESVILLE, Va., Nov. 21, 2018 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that company Chairman Bankole A. Johnson DSc, MD is being
Read more →ADILAdial Pharmaceuticals Engages CRO to Begin Phase 3 Clinical Trials of AD04 for the Treatment of Alcohol Use Disorder
CHARLOTTESVILLE, Va., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, and Crown CRO (“Crown”), a contract research organization based in Finland
Read more →ADILAdial Pharmaceuticals Provides Business Update for the Third Quarter of 2018
CHARLOTTESVILLE, Va., Nov. 14, 2018 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today provided a business update for the third quarter 2018, as well as re
Read more →ADILAdial Pharmaceuticals to Present at Dawson James Securities 4th Annual Small Cap Growth Conference
CHARLOTTESVILLE, Va., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that William Stilley, President and Chief Executive Office
Read more →ADILTreating Addiction Investor Presentation - September 2018 William Stilley, CEO
Treating Addiction Investor Presentation - September 2018 William Stilley, CEO 2 This presentation includes statements that are, or may be deemed, forward - looking statements.'' In some cases, these forward - l ooking statements can be identified by the use of forward - looking
Read more →ADILAdial Pharmaceuticals to Ring the Nasdaq Stock Market Opening Bell this Morning at 9:30 AM Eastern
CHARLOTTESVILLE, Va., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction and its lead drug for alcohol use disorder (AUD), will ring The Nasdaq Stoc
Read more →ADILAdial Pharmaceuticals Announces Appointment of Monika Rogozinska as Senior Vice President of Drug and Business Development
CHARLOTTESVILLE, Va., Aug. 15, 2018 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of a therapeutic agent for the treatment of alcohol use disorder, today announced the appointment of Mon
Read more →ADILAdial Pharmaceuticals Announces Closing of Initial Public Offering
CHARLOTTESVILLE, Va., July 31, 2018 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) (NASDAQ:ADILW), a clinical-stage biopharmaceutical company focused on the development of a therapeutic agent for the treatment of alcohol use disorder, today announced the closing of
Read more →ADILAdial Pharmaceuticals Announces Pricing of Initial Public Offering
CHARLOTTESVILLE, Va., July 27, 2018 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) (NASDAQ:ADILW), a clinical-stage biopharmaceutical company focused on the development of a therapeutic agent for the treatment of alcohol use disorder, today announced the pricing of
Read more →ADILADial Pharmaceuticals LLC Announces Issuance of First U.S. Patent
CHARLOTTESVILLE, Va., April 30, 2014 (GLOBE NEWSWIRE) -- ADial Pharmaceuticals, LLC (ADial), announced today the issuance of U.S. Patent No. 8,697,361 which covers the use of a serotonin-3 (5-HT3) antagonist for the treatment of alcohol related diseases, including Alcohol Use Dis
Read more →ADILADial Pharmaceuticals' Chairman, Bankole A. Johnson, to Head University of Maryland School of Medicine's New Brain Science Research Consortium
CHARLOTTESVILLE, Va., Feb. 19, 2014 (GLOBE NEWSWIRE) -- ADial Pharmaceuticals, LLC (ADial) announced today that Professor Bankole A. Johnson, D.Sc., M.D., the scientific founder and Chairman of the Board of ADial, will head a new Brain Science Research Consortium Unit (RCU) at th
Read more →ADILADial Pharmaceuticals Announces Strategic Partnership With Cato BioVentures
CHARLOTTESVILLE, Va., Nov. 4, 2013 (GLOBE NEWSWIRE) -- ADial Pharmaceuticals (ADial) announced today that it has entered into a strategic partnership with Cato BioVentures. Under the terms of the agreement, Cato BioVentures will invest up to $1.8 million in ADial, and Cato Resear
Read more →ADILADial Pharmaceuticals' Chairman, Dr. Bankole Johnson, to Present on Personalized Medicine at the ASAM State of the Art Course in Addiction Medicine
CHARLOTTESVILLE, Va., Oct. 23, 2013 (GLOBE NEWSWIRE) -- ADial Pharmaceuticals announced today that its Chairman, Bankole A. Johnson, D.Sc., M.D., will deliver a keynote presentation on Personalized Medicine as part of the American Society of Addiction Medicine's (ASAM) 2013 State
Read more →ADILADial Pharmaceuticals' Chairman, Bankole A. Johnson, Accepts Position at the University of Maryland School of Medicine
CHARLOTTESVILLE, Va., Aug. 21, 2013 (GLOBE NEWSWIRE) -- ADial Pharmaceuticals, LLC (ADial) announced today that Professor Bankole A. Johnson, D.Sc., M.D., the scientific founder and Chairman of ADial, has accepted a position as the Chair of the Department of Psychiatry at the Uni
Read more →ADILADial Pharmaceuticals Announces Publication of Study on AD04 for the Treatment of Patients With Alcohol Use Disorder
CHARLOTTESVILLE, Va., Aug. 12, 2013 (GLOBE NEWSWIRE) -- ADial Pharmaceuticals (ADial) announced today that the prestigious American Journal of Psychiatry ("AJP") has published a seminal article on the treatment of alcohol addiction using ADial's drug, AD04, in patients with selec
Read more →ADILADial Pharmaceuticals' Chairman, Dr. Bankole Johnson, Selected to Deliver 5th Annual Jack Mendelson Honorary Lecture at the National Institutes of Health
CHARLOTTESVILLE, Va., May 16, 2013 (GLOBE NEWSWIRE) -- ADial Pharmaceuticals announced today that its Chairman, Bankole A. Johnson, D.Sc., M.D., was selected by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), a unit of the National Institutes of Health (NIH), to d
Read more →Competitive Position
How ADIL ranks across every disease it competes inCompetitive Position is a premium feature
See how ADIL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial